TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27598342
Drug: Local muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local muscle vibration treatment (300 Hz, 30 minutes, 3 times per week for 12 sessions)
Study: 24960439
Drug: Unified Protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified Protocol for the Treatment of Emotional Disorders in Adolescence (UP-A)
Study: 22295884
Drug: Drotaverine hydrochloride
Normalized name: drotaverine hydrochloride
DrugBank: Drotaverine (DB06751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotaverine hydrochloride (80 mg)
Study: 19856067
Drug: Oral levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levofloxacin 500 mg once daily
Study: 14728019
Drug: Transfer for
Normalized name: SET,TRANSFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer for primary angioplasty without fibrinolytic treatment
Study: 9236500
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray 50 micrograms
Study: 9236500
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray 100 micrograms
Study: 9236500
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray 200 micrograms
Study: 9236500
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray 800 micrograms
Study: 8422174
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 12 mg/m2 of MMC on the day of operation, followed by 6 mg/m2 every 2 months for 6 times, and 600 mg/body of UFT continuously administered every day for 1 year.
Study: 8422174
Drug: Group D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D: 400 mg/body of UFT every day and the same amount of MMC as Group C.
Study: 8422174
Drug: UFT dosage
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT dosage per body weight (kg) of 8-12 mg/kg.
Study: 2446056
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 mg b.i.d. after 2 weeks of 20 mg b.i.d.)
Study: 2446056
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg N retard b.i.d.)
Study: 27488574
Drug: AMP XR-ODT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMP XR-ODT (18.8 mg)
Study: 27488574
Drug: AMP XR-ODT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMP XR-ODT (18.8 mg) with food
Study: 27488574
Drug: MAS ER
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAS ER (30 mg)
Study: 25376790
Drug: Apatinib 500
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500 mg daily on days 1 through 28 of each 4-week cycle
Study: 23760573
Drug: Tagatose (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tagatose (5 g)
Study: 23760573
Drug: Tagatose (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tagatose (10 g)
Study: 18213452
Drug: Simvastatin delayed
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin delayed release tablet (20 mg)
Study: 18213452
Drug: Simvastatin immediate
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin immediate release capsule (20 mg)
Study: 18213452
Drug: Simvastatin immediate
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin immediate release tablet Zocor (20 mg)
Study: 12612979
Drug: Atorvastatin in
Normalized name: Product containing atorvastatin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin in addition to ACE inhibitors and ARBs
Study: 12612979
Drug: No atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No atorvastatin in addition to ACE inhibitors and ARBs
Study: 8612120
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of astemizole
Study: 8612120
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of cetirizine
Study: 8612120
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of cetirizine
Study: 29117764
Drug: LAM + EC (counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM + EC (counseling and in advance provision of one packet of 0.75‐mg LNG‐ECPs)
Study: 29176387
Drug: CODJ-G (complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: CODJ-G (complex COD and plyometric protocol)
Study: 29176387
Drug: COD-G (isolated
Approvals — FDA: no, EMA: no, PMDA: no
Description: COD-G (isolated COD protocol)
Study: 27569118
Drug: Moderate daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate daily caloric restriction (CR)
Study: 25040146
Drug: 50% reduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% reduction of angiotensin inhibitor dose (n=30)
Study: 25040146
Drug: Standard basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard basal dose of angiotensin inhibitors (n=16)
Study: 14748937
Drug: High-protein, high-sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein, high-sodium diet (90 g/d protein, 180 mmol/d Na)
Study: 14748937
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet (70 g/d protein, 65 mmol/d Na)
Study: 7939431
Drug: Oral teicoplanin
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral teicoplanin 100 mg twice daily for 7 days (BID group)
Study: 7939431
Drug: Oral teicoplanin
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral teicoplanin 50 mg 4 times daily for 3 days, followed by 100 mg twice daily for 4 days (QID group)
Study: 3283457
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy with tamoxifen
Study: 3283457
Drug: Receptor-positive tumors
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receptor-positive tumors
Study: 3283457
Drug: Receptor-negative tumors
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receptor-negative tumors
Study: 23107971
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose gemcitabine (1,000 mg/m2) with carboplatin (AUC 5)
Study: 23107971
Drug: Low-dose prolonged
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prolonged infusion gemcitabine (350 mg/m2) with carboplatin (AUC 5)
Study: 20122038
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control group (two brief 'check-in' telephone calls during 6 months)
Study: 10235192
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg, clarithromycin 500 mg, and amoxicillin 1 g, all given b.i.d. for 10 days
Study: 10235192
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate, amoxicillin, and clarithromycin (10-day therapy)
Study: 8557125
Drug: Agonist administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agonist administered irrespective of cycle phase
Study: 7078423
Drug: Bendroflumethiazide 5
Normalized name: bendroflumethiazide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide 5 mg/day
Study: 28359339
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg for 2 weeks before surgery
Study: 28359339
Drug: No change
Approvals — FDA: no, EMA: no, PMDA: no
Description: No change to current statin therapy
Study: 22015451
Drug: Single-dose rasburicase
Normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single-dose rasburicase (0.15 mg/kg)
Study: 22015451
Drug: Daily dosing
Normalized name: Osmolex 322 MG Daily Dosing Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing of rasburicase for 5 days
Study: 19509098
Drug: Clomiphene, metformin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene, metformin, or combination of both for up to six cycles
Study: 17244248
Drug: Interferon-alpha-2a monotherapy
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha-2a monotherapy (9 MUI/day for 4 weeks and then 3 MUI/3 t.i.w. for 44 weeks)
Study: 17244248
Drug: Interferon-alpha-2a +
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha-2a + Amantadine (100 mg twice daily for 48 weeks)
Study: 17244248
Drug: Interferon-alpha-2a +
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha-2a + Ribavirin (1000-1200 mg)
Study: 9830234
Drug: Controlled-release 5-ISMN
Normalized name: ISMN
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release 5-ISMN 60 mg once daily
Study: 9830234
Drug: Conventional 5-ISMN
Normalized name: ISMN
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional 5-ISMN 20 mg twice daily
Study: 8132132
Drug: Melatonin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (2 to 10mg oral, given at bedtime)
Study: 3777565
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion method (Group B)
Study: 18562775
Drug: Low-GI/Low-GL meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-GI/Low-GL meal (L-L) - Carbohydrate content 65%, GI 40, GL 42
Study: 18562775
Drug: High-GI/Low-GL meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-GI/Low-GL meal (H-L) - Carbohydrate content 36%, GI 78, GL 44
Study: 9075595
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor-based treatment
Study: 11901278
Drug: Diuretic-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic-based treatment
Study: 3530834
Drug: 1% ciclopirox
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ciclopirox olamine cream
Study: 27329657
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg intravenous at 0, 2, and 6 weeks)
Study: 27329657
Drug: Ciclosporin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin (2 mg/kg/day intravenous for 7 days followed by 5.5 mg/kg/day oral until 12 weeks)
Study: 24576533
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment (various)
Study: 22105061
Drug: Buprenorphine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine therapy in an opioid treatment program (OTP) with individual counseling
Study: 22105061
Drug: Buprenorphine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine therapy in a group counseling program utilizing the Matrix Model (MMM)
Study: 22105061
Drug: Buprenorphine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine therapy in a private clinic setting mirroring standard medical management
Study: 15768813
Drug: 100 mg/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/l topical amphotericin B
Study: 15768813
Drug: 50 mg/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/l topical amphotericin B
Study: 9738066
Drug: BHI-VAN broth
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHI-VAN broth (brain heart infusion broth, horse serum, and yeast extract supplemented with vancomycin, amphotericin B, and nalidixic acid)
Study: 3046382
Drug: Imipramine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (low oral doses)
Study: 25624196
Drug: Long GnRH
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long GnRH agonist cycles
Study: 25624196
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist cycles
Study: 18756943
Drug: Activated carbon
Normalized name: Activated carbon
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated carbon nanoparticles injection (either by endoscopic injection or intraoperative subserosal injection)
Study: 18756943
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no activated carbon nanoparticles injection)
Study: 18756943
Drug: Activated carbon
Normalized name: Activated carbon
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated carbon nanoparticles injection
Study: 10037380
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily for 1 month
Study: 21808844
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg midazolam
Study: 7740908
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of meperidine 6.0 mg/mL, atropine 0.08 mg/mL, and diazepam 0.6 mg/mL (0.2 mL/kg)
Study: 2251993
Drug: Anticoagulants (heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants (heparin followed by phenprocoumon)
Study: 26418274
Drug: Intravenous ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ghrelin administration
Study: 19617841
Drug: Leg wrapping
Normalized name: Crab leg
DrugBank: Crab leg (DB11011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leg wrapping with tight elastic bandage plus placebo intravenous injections
Study: 17179052
Drug: Agalsidase beta
Normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Agalsidase beta (1 mg per kg of body weight) every 2 weeks for up to 35 months (median, 18.5 months)
Study: 17179052
Drug: Agalsidase beta
Normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Agalsidase beta (1 mg per kg of body weight) in protocol-adherent patients
Study: 17179052
Drug: Agalsidase beta
Normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Agalsidase beta (1 mg per kg of body weight) in patients with baseline eGFR > 55 mL/min per 1.73 m2
Study: 17179052
Drug: Agalsidase beta
Normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Agalsidase beta (1 mg per kg of body weight) in patients with baseline eGFR ≤ 55 mL/min per 1.73 m2
Study: 11531899
Drug: Alniditan 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alniditan 1.8 mg
Study: 9471290
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (lidocaine and prilocaine) applied before laser treatment
Study: 8509530
Drug: Single-stage tilt
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-stage tilt test with an infusion of 5 micrograms/min of isoproterenol
Study: 8509530
Drug: Multistage tilt
Normalized name: TILT-123
DrugBank: TILT-123 (DB17519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multistage tilt test with infusions of 0, 2 and 5 micrograms/min of isoproterenol
Study: 3543769
Drug: Mezlocillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin (4 g intravenously before surgery, second dose 4-6 hours later, final dose 6 hours after)
Study: 3543769
Drug: Placebo (saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline, same dosing schedule as mezlocillin)
Study: 23787458
Drug: Corneal collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corneal collagen crosslinking (CXL) treatment
Study: 21490140
Drug: DHA-rich fish-oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish-oil capsules (≈800 mg DHA/d)
Study: 21490140
Drug: Vegetable oil
Normalized name: Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable oil capsules (control group)
Study: 10761206
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (isosorbide‐5‐mononitrate and propranolol or nadolol)
Study: 10761206
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection sclerotherapy and endoscopic banding ligation
Study: 10761206
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy followed by semi‐emergency endoscopic therapy
Study: 8383415
Drug: 18 mg
Normalized name: niacin 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg iron daily
Study: 2463726
Drug: Acetated Ringer
Normalized name: ACETATED RINGER'S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetated Ringer solution (n = 45)
Study: 27692023
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (150 ml with dinner)
Study: 27692023
Drug: Mineral water
Normalized name: mineral water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral water (150 ml with dinner)
Study: 25313213
Drug: Rifampin Cmax
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin Cmax >8.2 mg/liter
Study: 25313213
Drug: Rifampin AUC
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin AUC <35.4 mg · h/liter
Study: 12772396
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba 100 mg daily
Study: 12772396
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 100 mg daily
Study: 9292184
Drug: Budesonide 128
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 128 micrograms once daily
Study: 9292184
Drug: Budesonide 256
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 256 micrograms once daily
Study: 3533454
Drug: Propafenone high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone high dosage (300 mg every eight hours)
Study: 3533454
Drug: Propafenone low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone low dosage (150 mg every eight hours)
Study: 28410250
Drug: Antigravity treadmill
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antigravity treadmill training (20 mins/d, 3 d/wk) together with traditional physical therapy for 3 months
Study: 27715335
Drug: Indacaterol/Glycopyrronium (IND/GLY)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/Glycopyrronium (IND/GLY) 110/50 μg once daily
Study: 24255993
Drug: 1‐h ultrasonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐h ultrasonic debridement with frequent oral hygiene reinforcement (OHI) over four visits
Study: 24255993
Drug: 1‐h ultrasonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐h ultrasonic debridement without frequent oral hygiene reinforcement (control)
Study: 19653573
Drug: Modafinil plus
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil plus oral scopolamine (MS)
Study: 17595750
Drug: Ranolazine in
Normalized name: Product containing ranolazine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine in combination with standard anti-anginal medications
Study: 17595750
Drug: Standard anti-anginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anti-anginal medications only
Study: 17595750
Drug: Ranolazine added
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine added to standard treatment
Study: 10215735
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d., metronidazole 500 mg b.d., clarithromycin 500 mg b.d. for 1 week
Study: 7474331
Drug: Azithromycin (AZM)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AZM) 500 mg once daily for 3 days
Study: 2081275
Drug: Bestatin 60
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bestatin 60 mg a day
Study: 7426081
Drug: Combined regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined regimen of nicotinic acid (up to 3 g daily) and 2 g of clofibrate daily
Study: 28716236
Drug: Hypoglycemic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemic treatment during hospitalization
Study: 28716236
Drug: No hypoglycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No hypoglycemic treatment during hospitalization
Study: 17564649
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 4 µg/kg
Study: 17564649
Drug: Transmucosal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmucosal dexmedetomidine 1 µg/kg
Study: 15151094
Drug: Neodolpasse (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neodolpasse (75 mg diclofenac and 30 mg orphenadine)
Study: 9486756
Drug: New SSRIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New SSRIs (fluvoxamine, paroxetine, sertraline)
Study: 9486756
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (nonteratogenic agents)
Study: 26380439
Drug: Compound Tongtu
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Tongtu Granule (CTG), 14.3 g per package, twice daily for 14 days
Study: 26380439
Drug: Placebo, 14.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 14.3 g per package, twice daily for 14 days
Study: 16722029
Drug: New bicarbonate/lactate-buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: New bicarbonate/lactate-buffered solution (N)